Literature DB >> 29785019

Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/β-catenin pathway.

José Manuel Cameselle-Teijeiro1,2, Diego Peteiro-González3, Javier Caneiro-Gómez4,5, María Sánchez-Ares4, Ihab Abdulkader4,5, Catarina Eloy6,7,8, Miguel Melo6,7,9,10, Isabel Amendoeira7,8,11, Paula Soares6,7,8, Manuel Sobrinho-Simões6,7,8,11.   

Abstract

Cribriform-morular variant of thyroid carcinoma is classically associated with familial adenomatous polyposis but, it can also occur as a sporadic neoplasm. This neoplasm is much more frequently observed in women than in men (ratio of 61:1). In familial adenomatous polyposis patients, tumors are generally multifocal and/or bilateral (multinodular appearance), whereas in the sporadic cases tumors tend to occur as single nodules. The tumors are well delimited, and characteristically show a blending of follicular, cribriform, papillary, trabecular, solid, and morular patterns. Neoplastic cells are tall or cuboidal with the occasional nuclear features of classic papillary thyroid carcinoma. The morules include cells with peculiar nuclear clearing and show positivity for CDX2 and CD10. Angioinvasion and capsular invasion have been described in about 30 and 40% of cases, respectively, with lymph node metastases in less than 10% of patients and distant metastases in 6%. Although this tumor has good prognosis, neuroendocrine and/or poor differentiation have been associated with aggressive behavior. Tumor cells can be focally positive or negative for thyroglobulin, but are always positive for TTF-1, estrogen and progesterone receptors, and negative for calcitonin and cytokeratin 20. Nuclear and cytoplasmic staining for β-catenin is the hallmark of this tumor type; this feature plays a role in fine needle aspiration biopsy. Cribriform-morular variant of thyroid carcinoma has a peculiar endodermal (intestinal-like) type phenotype, activation of the WNT/β-catenin signaling pathway, and belongs to the non-BRAF-non-RAS subtype of the molecular classification of thyroid tumors. Elevated expression of estrogen and progesterone receptors and activation of the WNT/β-catenin pathway may prove useful as putative therapeutic targets in cases that do not respond to conventional therapy. Clinicians should be alerted to the possibility of familial adenomatous polyposis when a diagnosis of cribriform-morular variant of thyroid carcinoma is made. Instead of being considered as a variant of papillary thyroid carcinoma its designation as cribriform-morular thyroid carcinoma seems more appropriate.

Entities:  

Mesh:

Year:  2018        PMID: 29785019     DOI: 10.1038/s41379-018-0070-2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

1.  Ghrelin Fights Against Titanium Particle-Induced Inflammatory Osteolysis Through Activation of β-Catenin Signaling Pathway.

Authors:  Ruize Qu; Xiaomin Chen; Yongjian Yuan; Wenhan Wang; Cheng Qiu; Long Liu; Peng Li; Zhaoyang Zhang; Krasimir Vasilev; Liang Liu; John Hayball; Yunpeng Zhao; Yuhua Li; Weiwei Li
Journal:  Inflammation       Date:  2019-10       Impact factor: 4.092

Review 2.  Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.

Authors:  Paula Soares; Antónia Afonso Póvoa; Miguel Melo; João Vinagre; Valdemar Máximo; Catarina Eloy; José Manuel Cameselle-Teijeiro; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2021-03-02       Impact factor: 3.943

Review 3.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

4.  Cribriform-morular variant of thyroid carcinoma.

Authors:  J M Cameselle-Teijeiro; M Sobrinho-Simões
Journal:  Pathologica       Date:  2019-03

5.  Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis.

Authors:  Vania Nosé; Ozgur Mete; Baris Boyraz; Peter M Sadow; Sylvia L Asa; Dora Dias-Santagata
Journal:  Endocr Pathol       Date:  2021-05-21       Impact factor: 4.056

Review 6.  Pitfalls in Challenging Thyroid Tumors: Emphasis on Differential Diagnosis and Ancillary Biomarkers.

Authors:  José Manuel Cameselle-Teijeiro; Catarina Eloy; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2020-07-06       Impact factor: 3.943

Review 7.  A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature.

Authors:  M D Aydemirli; K van der Tuin; F J Hes; A M W van den Ouweland; T van Wezel; E Kapiteijn; H Morreau
Journal:  Fam Cancer       Date:  2020-01       Impact factor: 2.375

8.  MicroRNA-4476 promotes glioma progression through a miR-4476/APC/β-catenin/c-Jun positive feedback loop.

Authors:  Jie Lin; Shengfeng Ding; Cheng Xie; Renhui Yi; Zhiyong Wu; Jie Luo; Tengyue Huang; Yu Zeng; Xizhao Wang; Anqi Xu; Jianqi Xiao; Ye Song; Xian Zhang
Journal:  Cell Death Dis       Date:  2020-04-23       Impact factor: 8.469

Review 9.  Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates.

Authors:  José Manuel Cameselle-Teijeiro; Ozgur Mete; Sylvia L Asa; Virginia LiVolsi
Journal:  Endocr Pathol       Date:  2021-01-25       Impact factor: 3.943

10.  Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components.

Authors:  Li-Li Wang; Li Ding; Peng Zhao; Jing-Jing Guan; Xiao-Bin Ji; Xiao-Li Zhou; Shi-Hong Shao; Yu-Wei Zou; Wei-Wei Fu; Dong-Liang Lin
Journal:  Dis Markers       Date:  2021-06-12       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.